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Background: Aberrant DNA methylation of promoter region CpG islands is an alternative mechanism that leads to
genetic defects in the inactivation of tumor suppressor genes during myelomagenesis. The aim of this study was to
examine the promoter methylation status of the phosphates and tensin homologue on chromosome 10 (PTEN)
gene in a cohort of multiple myeloma patients.
Findings: The PTEN gene was hypermethylated in 7 out of 58 (12%) primary myeloma samples. The correlation
between functional inactivation and PTEN mRNA levels was not statistically significant. The multiple myeloma
subgroup with an aberrant PTEN status had a prevalence of the component IgG, Salmon Durie stage I, lower lactate
dehydrogenase levels, intermediate-standard cytogenetic risk and longer overall survival with the respect to the
unmethylated subgroup.
Conclusions: This is the first report demonstrating the presence of PTEN promoter hypermethylation in multiple
myeloma.
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Background
Multiple myeloma (MM) is a B-cell neoplasm charac-
terized by end-organ damage, which may include hyper-
calcemia, renal dysfunction, anemia and lytic bone lesions.
MM comprises various biology entities with a hete-
rogeneous clinical course, ranging from a relatively benign
disorder to a highly aggressive disease with rapid progres-
sion. The MM pathogenesis is a multistage, complex
process where cytogenetic, molecular and epigenetic
mechanisms act together. It has been reported that during
myelomagenesis, DNA hypomethylation is the predo-
minant early change that is gradually transformed to DNA
hypermethylation in relapsed cases and during the pro-
gression of the disease [1,2]. Several malignancy-related
genes (VHL, XAF1, IRF8, TP53, CDKN2A-P16, CDKN2B,
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unless otherwise stated.genes) that affect various molecular pathways were shown
to be hypermethylated in MM, indicating that they
contribute to tumor formation and progression [3-5].
Promoter hypermethylation of CDKN2A, which is a
marker for overall epigenetic changes, and TGFBR2 have
been shown to correlate with poor prognosis in MM
patients, although the prognostic value of CDKN2A hyper-
methylation remains debatable [6]. Hypermethylation of
GPX3, RBP1, SPARC and TGFB1 genes was also demon-
strated to be associated with shorter overall survival.
The phosphates and tensin homologue on chromosome
10 gene (PTEN) is a tumor-suppressor gene known to be
mutated in multiple cancer [7,8]. PTEN regulates the cell
cycle progression, apoptosis, metastasis and invasion of
the tumor cells by negatively controlling the PI3P/Akt
pathway. It can be inactivated by mutation, loss of hete-
rozygosity, promoter hypermethylation, abnormal micro-
RNA expression and post-translational phosphorylation
[9]. PTEN alterations are detected, though sparsely, in
MM patients with advanced disease [10]. Abnormald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Association of clinical and laboratory parameters
















I 14 4 0.3
II 10 1
III 25 2
Age (mean in years) 67.6 ± 13.0 69 ± 10.1 0.7
White blood cells
(mean n°x10^3/mcL)
6.58 ± 2.2 6.0 ± 2.9 0.5
Hemoglobin (mean in g/dL) 10.2 ± 2.1 11.2 ± 1.9 0.2
Platelets (mean n°x10^3/mcL) 235 ± 95 210 ± 65 0.5
Lactate dehydrogenase
(mean in U/L)
379 ± 186 200 ± 40 0.01
β2-microglobuline (mg/dL) 5.3 ± 4.5 5.3 ± 5.4 0.9
Albumin (mean in g/dL) 3.6 ± 0.7 3.9 ± 0.8 0.3
Serum creatinine
(mean in mg/dL)
2.0 ± 2.35 1.0 ± 0.6 0.2
Calcium (mean in mg/dL) 6.0 ± 2.5 7.1 ± 2.5 0.3
Protein (mean in g/L) 8.5 ± 1.8 8.8 ± 1 0.66
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patients has been reported and may be associated with
disease progression and extramedullary infiltration
[11,12]. So far, PTEN deregulation has not been proven to
be due to epigenetic silencing. This study analyzed the
occurrence and the possible impact of PTEN epigenetic
status in a cohort of multiple myeloma patients.
Patients and methods
Clinical specimens
Bone marrow (BM) aspirates and clinical data from 58 pa-
tients with MM (30 male, 28 female; median age 67.8
years, range 29 to 86) were obtained during routine cli-
nical assessment at time of first diagnosis when the
patients were admitted to our hospital between 2000 and
2008, and for some, as the disease progressed. MM diag-
nosis was made in accordance with standard criteria, and
staging was according to the Salmon Durie Staging
System. MM clinical characteristics and laboratory para-
meters are reported in Table 1. Forty-six out of 58 (79.8%)
MM patients had an IgG monoclonal component, and
46.5% of patients were assigned Salmon Durie stage III.
Cytogenetic analysis data allowed us to categorize 62.1%
of the patients as high cytogenetic risk, defined by the
presence of t(4;14), t(14;16) or 17p13 deletion by
fluorescent in situ hybridization (FISH) analysis, while the
remaining patients were considered at intermediate
(presence of 1q gain, complex karyotype, deletion 13) or
standard risk (hyperdiploidy, t(11;14)) [13]. A total of 52
bone marrow aspirates from 12 patients with monoclonal
gammopathy of undetermined significance (MGUS), 10
with acute myeloid leukemia (AML), 10 with chronic
myeloid leukemia (CML), 10 with acute B lymphoblastic
leukemia (B-ALL) and 10 with myeloproliferative dis-
orders (MPD) were collected as part of the routine staging
procedure and analyzed. Seven bone marrow aspirates
obtained from patients with malignant lymphoma without
bone marrow infiltration were used as control samples.
The ASL Nuoro ethics committee approval and patient
informed consent were obtained.
Methylation analysis
High molecular weight DNA was isolated by the salting-
out method from bone marrow aspirates and was treated
with bisulphite for conversion of unmethylated but
not methylated cytosine to uracil using the CpGenome
DNA modification kit (Chemicon, Millipore SPA, (Italy).
Methylation-specific polymerase chain reaction (MSP)
was performed as initially described by Herman et al.
1996 [14]. Primers for the methylated and unmethylated
PTEN gene promoter regions, which amplified a region of
187 bp, were used [15]. In all experiments, DNA from
lymphoma specimens without bone marrow infiltration
were used as the negative control sample, and methylatedcontrol DNA (CpGenome Universal Methylated DNA,
Chemicon, Millipore SPA, Italy) was used as the positive
control. PCR products were analyzed on 2% agarose gels
and visualized under ultraviolet illumination.
Expression analysis
In a subset of 31 MM bone marrow specimens, analyzed
for PTEN gene promoter hypermethylation, total RNA
was isolated using Trizol reagent. The PTEN relative
expression level was analyzed in duplicate by quantitative
reverse transcriptase PCR using the TAMRA Probe
approach on ABI Prism 7500 (PE Applied Biosystems,
Foster City, CA). PTEN primers were: forward 5’- AA






Figure 1 PTEN gene hypermethylation analysis in multiple myeloma patients. (A) Representative methylation specific polymerase chain
reaction (MSP) results for PTEN in patient samples. The positive and negative controls showed the expected MSP results with normal DNA
showing positive U-MSP but negative M-MSP amplification, and conversely, the methylated control DNA showing negative U-MSP but positive
M-MSP amplification. (B) Kaplan-Meyer survival function of multiple myeloma (MM) patients with or without PTEN promoter hypermethylation,
P value = 0.53. (C) Heatmap of the PTEN analyses showing methylation status, quantitative reverse transcriptase PCR (qRT-PCR) for PTEN relative
gene expression and cytogenetic categories. MSP green, unmethylated; red, methylated; qRT-PCR: green, low expression; red, high expression and
white, not determined. Cytogenetics: green, standard risk; red, high risk. (D) Box and whisker plot showed the PTEN expression in methylated and
unmethylated primary MM patients, P value = 0.87. (E) Survival curves of 58 patients with multiple myeloma according to SD staging (P = 0.053),
and cytogenetic categories (P = 0.11).
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reference gene, and the 2-ΔΔCt method was used for data
analysis. Ten samples from MGUS patients and six
peripheral blood samples from controls were also evaluated.Statistical analysis
Differences between groups were analyzed using the
chi-squared test and were considered significant for
P value <0.05. The Kaplan-Meier method was used to
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Survival differences among comparator groups were
analyzed by the log-rank test. Statistical analyses were
done using SPSS 7.0 statistical software.
Results
Among the MM samples, the median overall survival
time (OS) was 37.7 months (Figure 1E). Moreover, the
median OS of patients with SD stage I, II and III were
91.8, 44.9, and 29.0 months, respectively (P = 0.039),
thereby suggesting that our MM patient group was an
unbiased myeloma cohort (Figure 1E). Stratification of
the MM patients according to cytogenetic risk categories
showed a median OS of 44.9 months for the standard
risk, 37.9 months for the intermediate risk and 19.3
months for the high risk group (P = 0.121).
MSP was used to analyze the methylation status of
PTEN in 58 MM, 52 patients with other hematological
malignancies and 7 ‘normal’ BM samples obtained from
non-infiltrated lymphomas. Aberrant promoter methyla-
tion was detected in 7 out of 58 (12%) diagnostic mye-
loma samples and in 2 out of 52 other hematological
samples (1 MPD and 1 B-ALL). None of the MGUS or
‘normal’ bone marrow controls showed aberrant methy-
lation of PTEN. Representative MSP results are shown
in Figure 1A.
When methylation results were analyzed for potential
correlations with MM clinical pathologic characteristics
including age, B2 microglobulin, lactate dehydrogenase
(LDH), serum creatinine, hemoglobin and calcium levels,
type of protein, type of light chain, Salmon Durie tumor
stage and cytogenetic abnormalities, no statistically sig-
nificant correlations were found, except for a lower level
of LDH (P = 0.01). Altogether, patients with aberrant
PTEN status had a prevalence of M component IgG, Sal-
mon Durie stage I, and lower LDH levels values at the
time of sampling and were classified as intermediate/
standard cytogenetic risk, except for a single high-risk
patient (Table 1).
When PTEN mRNA levels were measured to verify
whether PTEN gene hypermethylation could determine
loss of PTEN expression, results showed that the expres-
sion levels in MM samples differed significantly from
those of non-neoplastic tissues (mean value of -0.72 ± 14
versus 0.016 ± 0.30, respectively; P <0.001) and MGUS
(-0.72 ± 1.4 versus 0.14 ± 0.32, respectively; P = 0.0013).
No statistically significant correlation between loss of
PTEN expression and clinical parameters were found
except for the LDH (P = 0.001) and serum creatinine
(P = 0.02) levels (data not shown).
Furthermore, comparison of PTEN expression levels
in hypermethylated and unmethylated MM subgroups
did not reach a statistically significant difference with
mean values of 0.002 ± 0.23 and -0.03 ± 0.44, respectively(P = 0.85). Nevertheless, there was a tendency to lower
levels in the hypermethylated subgroup (Figure 1C,D).
Survival analysis did not show a statistically significant
difference between the hypermethylated and unmethy-
lated subgroup (P = 0.53). Thus, PTEN epigenetic status
did not have a prognostic impact on multiple myeloma
patients. However, the median overall survival of pa-
tients with PTEN methylation was longer that those with
an unmethylated promoter (median OS 91.8 versus 34.7
months).
Discussion
PTEN is involved in cellular differentiation, reproduction
and apoptosis, as well as cellular adhesion and mobility.
The loss or downregulation of PTEN plays an important
role in the multiple steps of tumorigenesis and progres-
sion of human malignancies. In hematological malignan-
cies, PTEN promoter was found hypermethylated in 20%
of acute lymphoblastic leukemia and chronic myeloid
leukemia cases, and it is also involved in the mechanism
determining imatinib resistance [17]. Our findings show
that PTEN is hypermethylated in a small proportion of
MM patients, indicating that epigenetic modification of
PTEN also may have a role in MM gene inactivation
mechanism besides mutations and gene deletions. This
MM subgroup had a prevalence of M component IgG,
Salmon Durie stage I, and intermediate/standard cyto-
genetic risk. Moreover, PTEN hypermethylation is linked
with low LDH level values when compared with those of
the unmethylated subgroup. We did not observe any
major effect of PTEN hypermethylation on overall sur-
vival, even though MM subgroup patients with aberrant
PTEN had a tendency to superior survival with respect
to unmethylated patients according to their clinical stage
and laboratory parameters. We have hypothesized that
other factors, such as regimen treatments, may have a
role. In agreement with other studies, we found abnor-
mal expression of PTEN in myeloma primary samples,
but in our cohort, low levels of PTEN expression were
associated with low levels of LDH and serum creatinine,
signs of a less aggressive disease. In addition, we found
that PTEN deregulation is independent or weakly asso-
ciated with its epigenetic status, suggesting a lack of
functional consequence to PTEN methylation. There is
evidence that in leukemia samples PTEN expression
does not correlate with functional inactivation and other
defects in which regulatory mechanisms may act.
In conclusion, PTEN hypermethylation is observed in
MM samples, but it affects neither gene expression nor
clinical outcome. Since PTEN is one of the potential tar-
gets along the PI3K/Akt pathway, the modulation of its
expression is a potential strategy for treatment of MM
[18-20], and further studies are needed to investigate the
PTEN inactivation process in multiple myeloma.
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